The stock of Heron Therapeutics Inc (HRTX) has seen a -1.11% decrease in the past week, with a -10.10% drop in the past month, and a -43.49% decrease in the past quarter. The volatility ratio for the week is 5.99%, and the volatility levels for the past 30 days are at 7.08% for HRTX. The simple moving average for the past 20 days is -6.88% for HRTX’s stock, with a -31.91% simple moving average for the past 200 days.
Is It Worth Investing in Heron Therapeutics Inc (NASDAQ: HRTX) Right Now?
The stock has a 36-month beta value of 1.80. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HRTX is 144.09M, and at present, short sellers hold a 22.00% of that float. On October 23, 2024, the average trading volume of HRTX was 2.12M shares.
HRTX) stock’s latest price update
The stock of Heron Therapeutics Inc (NASDAQ: HRTX) has decreased by -1.66 when compared to last closing price of 1.81.Despite this, the company has seen a loss of -1.11% in its stock price over the last five trading days. prnewswire.com reported 2024-10-10 that SAN DIEGO, Oct. 10, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today reaffirmed the Company’s ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting (“CINV”) prevention and APONVIE® for Postoperative Nausea and Vomiting (“PONV”) prevention given the temporary shortage of intravenous (“IV”) fluids which is expected as the result of Hurricane Helene. As alternatives to products that require dilution with IV fluids, CINVANTI, SUSTOL, and APONVIE are supplied in ready-to-administer formulations that do not require additional dilution with IV fluids in what may be a time of critical shortage.
Analysts’ Opinion of HRTX
Many brokerage firms have already submitted their reports for HRTX stocks, with Rodman & Renshaw repeating the rating for HRTX by listing it as a “Buy.” The predicted price for HRTX in the upcoming period, according to Rodman & Renshaw is $7 based on the research report published on June 13, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see HRTX reach a price target of $6. The rating they have provided for HRTX stocks is “Overweight” according to the report published on April 23rd, 2024.
Needham gave a rating of “Buy” to HRTX, setting the target price at $5 in the report published on March 13th of the current year.
HRTX Trading at -6.64% from the 50-Day Moving Average
After a stumble in the market that brought HRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.71% of loss for the given period.
Volatility was left at 7.08%, however, over the last 30 days, the volatility rate increased by 5.99%, as shares sank -9.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.17% lower at present.
During the last 5 trading sessions, HRTX fell by -1.11%, which changed the moving average for the period of 200-days by +0.56% in comparison to the 20-day moving average, which settled at $1.9115. In addition, Heron Therapeutics Inc saw 4.71% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HRTX starting from Forbes William P, who purchase 25,000 shares at the price of $1.09 back on Nov 17 ’23. After this action, Forbes William P now owns 79,000 shares of Heron Therapeutics Inc, valued at $27,250 using the latest closing price.
Forbes William P, the EVP, Chief Development Officer of Heron Therapeutics Inc, purchase 50,000 shares at $0.94 during a trade that took place back on Nov 16 ’23, which means that Forbes William P is holding 54,000 shares at $46,995 based on the most recent closing price.
Stock Fundamentals for HRTX
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.65 for the gross margin
The net margin for Heron Therapeutics Inc stands at -0.35. The total capital return value is set at -0.34.
Based on Heron Therapeutics Inc (HRTX), the company’s capital structure generated 1.27 points at debt to capital in total, while cash flow to debt ratio is standing at -0.12. The debt to equity ratio resting at -4.68. The interest coverage ratio of the stock is -16.99.
Currently, EBITDA for the company is -107.72 million with net debt to EBITDA at -3.68. When we switch over and look at the enterprise to sales, we see a ratio of 3.16. The receivables turnover for the company is 1.85for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.38.
Conclusion
To sum up, Heron Therapeutics Inc (HRTX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
